Sight Sciences (NASDAQ:SGHT – Get Rating) is a person of 216 publicly-traded providers in the “Surgical & healthcare instruments” market, but how does it weigh in in comparison to its friends? We will evaluate Sight Sciences to associated enterprises based mostly on the strength of its analyst tips, institutional ownership, valuation, threat, profitability, dividends and earnings.
Earnings and Valuation
This table compares Sight Sciences and its friends income, earnings for each share and valuation.
| Gross Income | Internet Money | Price/Earnings Ratio | |
| Sight Sciences | $48.96 million | -$62.96 million | -3.40 |
| Sight Sciences Competition | $1.15 billion | $84.66 million | -537.77 |
Sight Sciences’ peers have larger earnings and earnings than Sight Sciences. Sight Sciences is investing at a higher cost-to-earnings ratio than its peers, indicating that it is at this time far more highly-priced than other businesses in its sector.
Profitability
This desk compares Sight Sciences and its peers’ internet margins, return on fairness and return on assets.
| Web Margins | Return on Equity | Return on Property | |
| Sight Sciences | -134.02% | -51.67% | -33.54% |
| Sight Sciences Opponents | -748.20% | -65.14% | -19.63% |
Analyst Ratings
This is a breakdown of current suggestions for Sight Sciences and its friends, as reported by MarketBeat.
| Market Ratings | Hold Scores | Invest in Ratings | Potent Obtain Scores | Ranking Rating | |
| Sight Sciences | 5 | 3.00 | |||
| Sight Sciences Competition | 1308 | 4640 | 8023 | 221 | 2.50 |
Sight Sciences presently has a consensus concentrate on price tag of $31.00, indicating a possible upside of 194.68%. As a team, “Surgical & professional medical instruments” businesses have a likely upside of 54.70%. Specified Sight Sciences’ more powerful consensus score and greater possible upside, analysts plainly consider Sight Sciences is much more favorable than its peers.
Insider & Institutional Possession
60.8% of Sight Sciences shares are owned by institutional buyers. Comparatively, 51.2% of shares of all “Surgical & professional medical instruments” companies are owned by institutional traders. 14.4% of shares of all “Surgical & health care instruments” providers are owned by insiders. Solid institutional ownership is an indication that endowments, hedge money and substantial dollars supervisors believe that a organization will outperform the current market above the prolonged expression.
Summary
Sight Sciences beats its peers on 7 of the 12 variables compared.
Sight Sciences Company Profile (Get Ranking)
Sight Sciences, Inc., an ophthalmic health-related device organization, engages in the advancement and commercialization of surgical and nonsurgical systems for the treatment method of eye disorders. The firm’s solutions include OMNI Surgical Process, a therapeutic gadget made use of by ophthalmic surgeons to lower intraocular tension in adult glaucoma patients and TearCare Program, a wearable eyelid engineering for the therapy of dry eye condition (DED) for ophthalmologists and optometrists. It features its merchandise via product sales reps and distributors to hospitals, medical facilities, and eyecare professionals in the United States. The organization was integrated in 2010 and is headquartered in Menlo Park, California.
Receive News & Scores for Sight Sciences Every day – Enter your e-mail handle underneath to acquire a concise day by day summary of the newest information and analysts’ ratings for Sight Sciences and similar companies with MarketBeat.com’s Totally free each day email publication.